Clinical Trial Update: Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial NAFLD HEROES is evaluating the hepatic effects of semaglutide in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. The…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Fatty Liver Disease
• Non-alcoholic Steatohepatitis

Drugs mentioned

• semaglutide (semaglutide)

Snippet

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Conditions: Non-Alcoholic Steatohepatitis, Non-Alcoholic Fatty Liver Disease | Phase 2 | Status: RECRUITING